Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):678-85.
View in:
PubMed
subject areas
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Analysis of Variance
Analysis of Variance
Antineoplastic Agents
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Capecitabine
Capecitabine
Carcinoma, Pancreatic Ductal
Carcinoma, Pancreatic Ductal
Chemoradiotherapy, Adjuvant
Chemoradiotherapy, Adjuvant
Deoxycytidine
Deoxycytidine
Drug Eruptions
Drug Eruptions
Erlotinib Hydrochloride
Erlotinib Hydrochloride
Female
Female
Fluorouracil
Fluorouracil
Humans
Humans
Male
Male
Middle Aged
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Pancreatectomy
Pancreatectomy
Pancreatic Neoplasms
Pancreatic Neoplasms
Pancreaticoduodenectomy
Pancreaticoduodenectomy
Quality of Life
Quality of Life
Quinazolines
Quinazolines
Radiotherapy, Intensity-Modulated
Radiotherapy, Intensity-Modulated
authors with profiles
Barish H Edil